

SYMPOSIUM AGENDA

2024 Annual Updates in Hematology Symposium

Saturday, March 30, 2024
9:30 AM – 2:30 PM

The University of Tennessee Health Science Center (UTHSC)
Mooney Building Library, Room 201
875 Monroe Avenue • Memphis, TN 38163

9:30 - 10:30 AM	Registration, Breakfast, Exhibitors
10:30 - 10:35 AM	Welcome/Opening Remarks Noura Elsedawy, MD
10:35 - 10:45 AM	Pre-event Questions Noura Elsedawy, MD
10:45 - 11:10 AM	Oral Therapy for PNH and Treatments on the Horizon for Myeloid Neoplasms Swapna Thota, MD
11:10 - 11:30 AM	Approaches to Induction in TE NDMM Muhammed Baljevic, MD
11:30 - 11:50 AM	RPMM - The Road from Relapsed to Refractory Noura Elsedawy, MD
11:50 - 12:25 PM	Lunch, Exhibitors
12:25 - 12:45 PM	Cardiac Amyloidosis: A Cardiologist's Perspective Isaac B. Rhea, MD
12:45 - 1:05 PM	Curative Therapies for Sickle Cell Disease Brion Randolph, MD
1:10 - 1:30 PM	Evolving Treatment Landscape of Lymphoma Muhammad Saad Hamid, MD
1:30 - 1:50 PM	Updates in Hemophilia Management Rohith Jesudas, MBBS
1:50 - 2:05 PM	Question and Answer Muhammad Saad Hamid, MD
2:05 - 2:20 PM	Panel Discussion
2:20 - 2:30 PM	Closing Remarks Muhammad Saad Hamid, MD

REGISTRATION

Space is limited. Online registration is available at:
<https://cenow.uthsc.edu/content/2024-hematology-symposium>
There is no cost to attend this symposium.

ACTIVITY LOCATION

The University of Tennessee Health Science Center
Mooney Building, Library, Room 201
875 Monroe Avenue
Memphis, TN 38163

PARKING

Parking is available in the following two garages:

- **Hamilton Eye Institute Parking Garage (H Lot)**
Distance: 7-minute walk
Location: Madison Avenue at Pauline Street
(across from Landau Uniforms)
- **GEB Parking Garage (E Lot)**
Distance: 5-minute walk
Location: West of the College of Pharmacy building

CONTACT INFORMATION

Britney Brown
UTHSC Cancer Program
Phone: (901) 376-3554
Email: bbrow130@uthsc.edu

*The University of Tennessee is an
EEO/AA/Title VI/Title IX/Section 504/ADA/ADEA
institution in the provision of its education and
employment programs and services.*



2024 Annual Updates in Hematology Symposium

Saturday, March 30, 2024
9:30 AM – 2:30 PM

The University of Tennessee
Health Science Center (UTHSC)
Mooney Building Library, Room 201
875 Monroe Avenue
Memphis, TN 38163



OVERVIEW

The 2024 Annual Updates in Hematology Symposium is designed to provide hematology and oncology providers with a state-of-the-art update on hematologic malignancies and blood disorders. It will tackle the latest scientific updates, innovative ideas, and timeliest questions related to the management and care of these challenging conditions. It is also designed to provide a networking opportunity for healthcare professionals, who care for patients with blood cancers and disorders in the Mid-South, to establish collaborative pathways to improve the management and outcomes of this patient population.

EDUCATIONAL OBJECTIVES

- Identify guidelines to plan and implement individualized treatment decisions for patients with select blood cancers and disorders by leveraging data from molecular and genetic updates.
- Evaluate the latest evidence-based data from clinical trials for emerging therapeutic strategies for select blood cancers and disorders.
- Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts.

DESIRED OUTCOME

The goal of the 2024 Annual Updates in Hematology Symposium is to provide participants with information to improve patient management and care strategies. This goal will be accomplished by discussing rapidly evolving developments and improved practice paradigms. The symposium will provide learners with enhanced knowledge of evidence-based data related to best practices for treating select blood cancers and disorders and inform them of the indications to refer patients for expert quaternary-level care. Panel discussions, along with question-and-answer sessions that include collaborative sharing of information and research, as well as networking with other healthcare professionals have shown to improve participant knowledge and competency. Additionally, it will build a connected community of hematologic care providers across the region.

FACULTY AND GUEST SPEAKERS



Muhamed Baljevic, MD
Associate Professor
Division of Hematology / Oncology
Director, Plasma Cell Disorders Research of
Vanderbilt-Ingram Cancer Center
Director, Vanderbilt Amyloidosis Multidisciplinary
Program (VAMP)
of Vanderbilt-Ingram Cancer Center
Vanderbilt University




Noura Elsedawy, MD
Assistant Professor
Division of Hematology / Oncology
UTHSC



Muhammad Saad Hamid, MD
Assistant Professor
Division of Hematology / Oncology
UTHSC



Rohith Jesudas, MBBS
Assistant Professor
Department of Hematology
St. Jude Children's Research Hospital



Brion Randolph, MD
Associate Professor
Division of Hematology / Oncology
UTHSC



Isaac B. Rhea, MD
Assistant Professor
Division of Cardiology
UTHSC



Swapna Thota, MD
Associate Professor
Division of Hematology / Oncology
UTHSC

DISCLOSURE STATEMENT

The University of Tennessee College of Medicine is committed to providing CME that is balanced, objective, and evidence based. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards, all parties involved in content development are required to disclose any real or apparent conflicts of interest relating to the topics of this educational activity. The University of Tennessee College of Medicine has established mechanisms to resolve conflicts of interest should they arise. Any potential conflict of interest or off label use will be disclosed to the audience prior to the activity.

3.25 CME / CEU credits provided



AMA Credit Designation:

The University of Tennessee College of Medicine (UTCOM) designates this live activity for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education for Non-Physicians:

The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.

Accreditation:

The UTCOM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

TARGET AUDIENCE

Primary care physicians, hematologists, pathologists, medical oncologists, nurse practitioners, fellows, residents, medical students, and other healthcare professionals dedicated to treating blood cancers and disorders.

ACTIVITY MEDICAL DIRECTORS

Noura Elsedawy, MD

Assistant Professor
Division Hematology / Oncology
UTHSC

Muhammad Saad Hamid, MD

Assistant Professor
Division Hematology / Oncology
UTHSC